Drugs / URLC10-117
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00673777 | May 2008 → Apr 2009 | non-small cell lung carcinoma | Tokyo University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00674258 | May 2008 → Apr 2009 | non-small cell lung carcinoma | Tokyo University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | URLC10-117 | “On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.” NCT00674258 ↗1“the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51” NCT00673777 ↗ |
| Modality | Peptide | “the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51” NCT00673777 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT00674258 ↗ |